Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)

ConclusionsFive-weekly SP therapy combined with trastuzumab therapy showed a good antitumor response and acceptable toxicity in HER2-positive advanced GC/EGJC. Serum neuregulin  1 might be associated with the efficacy of this treatment regimen.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research